1 Simultaneous assessment of genetic and epigenetic contributions to plasma lipid levels with 2 respect to cardiovascular risk 3 4 Fumihiko Takeuchi, PhD ^{1,2}; Masaya Yamamoto, MD ³; Masahiro Nakatochi, PhD ⁴; Kozue Takano, PhD ^{2,5}; Atsuko Okazaki, MD⁵; Sakurako Emoto, MD³; Yasuharu Tabara, PhD⁶; Tomohiro Katsuya, MD^{7,8}; 5 6 Ken Yamamoto, MD⁹; Masato Isono, PhD¹; Kotaro Mori, PhD²; Tatsuaki Matsubara, MD¹⁰; Sahoko 7 Ichihara, MD¹¹; Mitsuhiro Yokota, MD¹²; Hisao Hara, MD³; Yukio Hiroi, MD³; Norihiro Kato, MD^{1,2,5*} 8 9 ¹Department of Gene Diagnostics and Therapeutics, Research Institute, National Center for Global 10 Health and Medicine 11 ² Medical Genomics Center, Research Institute, National Center for Global Health and Medicine 12 ³ Department of Cardiology, Center Hospital, National Center for Global Health and Medicine 13 ⁴ Public Health Informatics Unit, Nagoya University Graduate School of Medicine 14 ⁵ Department of Genomic Medicine, Center Hospital, National Center for Global Health and Medicine 15 ⁶ Graduate School of Public Health, Shizuoka Graduate University of Public Health 16 ⁷ Department of Clinical Gene Therapy, Osaka University Graduate School of Medicine 17 ⁸ Department of Geriatric Medicine and Nephrology, Osaka University Graduate School of Medicine 18 ⁹ Department of Medical Biochemistry, Kurume University School of Medicine 19 ¹⁰ Faculty of Human Sciences, Aichi Mizuho College 20 ¹¹Department of Environmental and Preventive Medicine, Jichi Medical University School of 21 Medicine 22 ¹²Kurume University School of Medicine 23 24 Short title: Genetic and epigenetic risk prediction of lipids 25 26 * Corresponding author 27 Norihiro Kato 28 1-21-1 Toyama, Shinjuku-ku, Tokyo, 162-8655, JAPAN 29 Email: nokato@ri.ncgm.go.jp 30

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

Total word count of the manuscript: 7,067 words (in main text)

31

33

34

35

36

37

38

39

40

41

42

43

44

45

46

47

48

49

50

51

52

53

54

2

Abstract (limited to 250 words) **Background**: This study aims to develop a model for simultaneously assessing genetic and epigenetic contributions to plasma lipid levels. Methods: The predictive model was developed using two cardiovascular risk groups, i.e., individuals with high low-density lipoprotein cholesterol (LDL-C) levels (≥160 mg/dl, N = 296) and coronary artery disease (CAD) (N = 315), in contrast to reference (max N = 3,801) and non-CAD individuals (N = 164). For genetic predisposition, rare pathological variants in five target genes related to familial hypercholesterolemia (FH) were screened, while common variants were characterized to calculate a polygenic risk score (PRS). The methylation risk score (MRS) was also calculated for epigenetic profiles based on DNA methylation levels at 13 CpG sites. A relationship between these variables and lipid levels was analyzed in regression and quantile models. Results: A total of 17 rare FH-related gene variants were identified in patients with high LDL-C or CAD, significantly more prevalent than in the general Japanese population (2.8% vs. 0.2%, P <1×10⁻¹⁵). For the rare variants plus PRS, the predictability of individual LDL-C increased (correlation coefficient between predicted and measured values, r = 0.261, $P = 1.7 \times 10^{-11}$) compared to PRS alone (r = 0.151, $P = 1.2 \times 10^{-4}$). PRS and MRS had the most significant impact on high-density lipoprotein cholesterol and triglycerides, respectively. The two risk scores had additive effects on these traits. **Conclusions**: Our results provide proof-of-concept that assessing the relative contribution of genetic predisposition and DNA methylation levels (reflecting past environmental exposures) may help

Key Words: Genetic risk score; Plasma lipids; Coronary artery disease; DNA methylation

individuals refine their dyslipidemia treatment.

Dyslipidemia is a significant risk factor for atherosclerotic cardiovascular diseases, including coronary artery disease (CAD), to which genetic, environmental, and demographic factors contribute interactively. Epidemiological studies have shown that appropriate management of dyslipidemia can significantly decrease cardiovascular morbidity and mortality. Atherosclerosis treatment has often focused on reducing low-density lipoprotein cholesterol (LDL-C) among dyslipidemias, with lifestyle modifications emphasized in all patients with high LDL-C.^{1,2} Above all, dietary intervention is essential because high saturated fat intake causes increased concentrations of LDL-C.³ However, sustaining lifestyle modifications over time is generally challenging, so drug therapy is sometimes necessary to reduce the risk of atherosclerosis.¹

People with a vital genetic component, e.g., familial hypercholesterolemia (FH) patients, also require lipid-lowering medications such as statins at an earlier stage.² For CAD, while the introduction of statins has considerably changed its management and prevention, the disease burden remains high. Clinical practice guidelines emphasize the importance of estimating the absolute risk of CAD and tailoring the intensity of preventive actions accordingly.^{1,4} The optimal LDL-C goal for persons at low risk is set at <116 mg/dl by the 2019 ESC Guidelines, which used to be set at <160 mg/dl (for persons with 0-1 risk factor) by the NCEP-ATPIII Guidelines. Still, there is a significant gap between guideline-recommended treatment and daily clinical practice of dyslipidemia.⁵

An individual's lipid levels are influenced by the degree of environmental exposure and genetic predisposition, although no method has been established to provide quantitative indicators of these combinations. On the one hand, it is difficult to quantitatively assess the impact of unhealthy lifestyle habits on lipid levels. Even so, exposure to some external factors, such as smoking and high plasma lipids, can cause long-lasting DNA methylation changes in blood cells.⁶⁻⁸ These changes can reflect an individual's environmental history, and consequently, lifestyle habits may be evaluated through epigenetic biomarkers.⁹ On the other hand, genetic information as an auxiliary diagnostic tool for dyslipidemia is still in the realm of research, with a few exceptions, such as the genetic diagnosis of FH.² In this line, polygenic risk score (PRS) has recently become popular to summarize the cumulative effects of genetic loci, successfully identified by genome-wide association studies (GWAS) of lipid traits.^{8,10} Nonetheless, there remains considerable uncertainty in individual PRS estimation for PRS-

based risk stratification¹¹ and substantial difficulty in unbiased assessment of the contribution of rare variants to complex traits.¹²

In light of this situation, we performed genetic (i.e., GWAS array genotyping and rare variant search in FH-related target genes) and epigenetic (specifically, DNA methylation) analyses focusing on lipid traits, specifically LDL-C. We aim to develop a model for evaluating genetic and epigenetic contributions to plasma lipid levels with a risk prediction index simultaneously incorporating multiple data modalities for individuals with high LDL-C or CAD. We studied Japanese populations to overcome challenges in applying PRS and methylation profiles to non-European ancestry groups. ^{13,14} We collected individual-level data to test our risk prediction index's accuracy. The study demonstrates that a combination of genetic predisposition and DNA methylation has an additive effect on an individual's lipid levels among people at high risk of atherosclerosis and supports the potential utility of multi-omics data in refining an individual's dyslipidemia treatment.

Materials and Methods

Please see the Data Supplement for details about the Materials and Methods.

Study population: The institutional ethics review board approved this study, and participants gave their written informed consent. The procedures followed the ethical standards of the institutional committee on human experimentation at the National Center for Global Health and Medicine (NCGM).

In NCGM, adult patients of Japanese descent were recruited via two separate projects: BIO-CVD and NCGM Biobank, whose enrollment started in 2014 and 2012, respectively. They were categorized into three subgroups based on their plasma LDL-C levels and CAD status (see Supplementary Methods): high LDL-C without CAD, CAD, and non-CAD subgroups (as shown in Table 1). A hospital-based study called BIO-CVD assessed CAD in 475 participants (306 CAD and 169 non-CAD). Samples from the NCGM Biobank were also examined, specifically those with elevated plasma LDL-C (\geq 160 mg/dl) (N = 300). These samples were used for genetic and DNA methylation analyses (Fig. 1). Also, a significant number of Japanese individuals from non-targeted populations were included. We used publicly available whole genome sequencing data (N = 8.3K) for low-frequency (or rare) genetic

112

113

114

115

116

117

118

119

120

121

122

123

124

125

126

127

128

129

130

131

132

133

134

135

136

137

138

5

variants. For common single nucleotide variants (SNVs), we used GWAS array genotyping data in three population-based cohorts (including the Kita-Nagoya Genomic Epidemiology [KING] study cohort¹⁵) and another hospital-based sample at NCGM (named NCGM hospital cohort; N = 351) (Table S1), which we referred to hereafter as reference individuals in total (N = 3,801). Furthermore, for DNA methylation, we utilized epigenome-wide association study (EWAS)-array assayed data for part (N = 314) of the KING study cohort samples previously reported.¹⁵ When analyzing prediction models for dyslipidemia, the high LDL-C and CAD subgroups were set as atherosclerotic risk groups, while the KING study cohort samples and the non-CAD subgroup were set as comparison groups (Fig. 1). With these subgroup analyses, we attempted to test whether high LDL-C or CAD status affects the association between DNA methylation and lipid traits. Medical records were reviewed to extract the participants' plasma lipid levels and medication information at enrollment and clinical conditions of CAD patients (Table 1). To ensure the reliability of the data, we excluded individuals who had missing information on key variables: plasma lipid levels, genotype, and DNA methylation data. Imputation of baseline LDL-C level: For the imputation of baseline (or pretreatment) LDL-C, we performed a retrospective analysis on data from 36 individuals with high LDL-C in whom plasma LDL-C measurements were available both before and within 18 months after initiating statins and ezetimibe (Fig. S1). Similar to the study by Ruel et al., 16 we performed imputation of baseline LDL-C by dividing the on-treatment value by the proportion obtained by subtracting the expected treatment-induced reduction (expressed as a ratio) from 1. Gene sequencing: Next-generation sequencing screened mutations in five FH-related genes (LDLR, APOB, PCSK9, LDLRAP1, and APOE). The sequences were aligned to a human genome reference sequence (GRCh37/hg19). SNVs and insertion/deletion (Indel) were called using the software GATK (https://gatk.broadinstitute.org/) and McCortex (https://github.com/mcveanlab/mccortex) and annotated using VarSeq (https://www.goldenhelix.com/products/VarSeq/). We then retrieved rare, putatively pathogenic variants, including SNVs that cause non-synonymous, nonsense, or splice-site substitutions and are predicted to be deleterious by ClinVar, LOVD, or in silico prediction algorithms in dbNSFP.¹⁷

140

141

142

143

144

145

146

147

148

149

150

151

152

153

154

155

156

157

158

159

160

161

162

163

164

165

166

6

Genotyping: 767 samples were newly genotyped with the Infinium OmniExpress-24 BeadChip (Illumina, San Diego, CA, USA). Besides, GWAS array genotyping data for reference individuals were utilized. Polygenic risk score (PRS): For each lipid trait, a PRS was built using LDpred (https://github.com/bvilhjal/ldpred)¹⁹ and external GWAS summary statistics,²⁰ for which potential population stratification was adjusted using genetic principal components. ²¹ Briefly, for each linkage disequilibrium (LD)-based clump across the genome, index SNPs passing specific statistical significance (P < 0.005) and LD coefficient ($r^2 \ge 0.5$) thresholds were extracted from large GWAS reported in Japanese.²⁰ Individuals were scored based on the number of risk alleles (0, 1, or 2) weighted by beta of the SNP-trait association, thereby used for developing the best polygenic predictive indicator of LDL-C (PRS_{LDL-C}) and other lipid traits. Conversion of PRS to LDL-C value: We developed a formula that converts PRSs to LDL-C values using two different external reference panels to estimate the standardized effects of a PRS_{LDL-C} on plasma LDL-C level. First, we set standardized PRS_{LDL-C} decile classes in the general Japanese population and used them as the Japanese standard PRS for LDL-C (Fig. S2A-C). Then, we calculated the mean LDL-C values for Japanese standard PRS decile classes in the NCGM hospital cohort, which was not previously screened for cardiovascular disease (Table S1 and Fig. S3). The mean values of LDL-C for each PRS decile class (shown in Fig. S2D) were used to convert PRS_{LDL-C} in individuals from BIO-CVD and NCGM Biobank (Fig. 3D and Fig. S2E) belonging to the same population as the NCGM hospital cohort. Genetic composite risk: For rare [minor allele frequency (MAF) < 0.01] variants of putative functional significance, we arbitrarily classified them into three distinct categories—(1) disruptive (frameshift or splice-donor), (2) damaging, and (3) all other non-synonymous variants—similar to the previous study²² with some modifications (see the Supplementary Methods). We estimated the net increase in LDL-C levels for rare variant carriers by subtracting a predicted value (based on PRS_{LDL-C}) from the actual measured value. Using linear regression models, we calculated LDL-C changes from individuals without rare FH-related gene variants and the standard error (SE) by category, including disruptive, damaging, and other non-synonymous variants.

168

169

170

171

172

173

174

175

176

177

178

179

180

181

182

183

184

185

186

187

188

189

190

191

192

193

194

7

To combine the genetic risk of rare variants and SNVs, we used the following algorithm: [an individual's LDL-C value] = [predicted LDL-C value based on PRSLDL-C] + [estimated changes from noncarriers (by rare variant category)]. Methylation risk score (MRS): Genomic DNA was extracted from the peripheral blood buffy coat and stored at -80°C for DNA methylation analysis. As previously reported, ²³ genome-wide methylation profiling was performed with the Illumina EPIC array (Illumina Inc. San Diego, CA, U.S.A.). Also, droplet digital PCR (ddPCR) assay in the QX200 Droplet Digital PCR system (Bio-Rad, Carlsbad, CA, U.S.A.) was employed to measure methylation extent at 13 selected CpG sites, which had been reported to show robust evidence for association with lipid traits in previous EWASs (Supplementary Methods, Table S3).10 Because methylation profiles reflect environmental effects, MRSs were created for lipid traits using weighted sums of beta values from 13 CpG sites.²⁴ Here, the effect sizes from the previous multi-ancestry EWAS for lipid traits¹⁰ were utilized as external weights for each CpG probe. Statistical analysis: Pearson's correlation coefficient, r, was calculated to measure the strength and direction of the linear relationship between actual lipid levels and those predicted by the individual risk score models. To develop a prediction model, the relationship between predictor variables (i.e., PRS, MRS, and/or PRS+MRS) and outcome variables (i.e., plasma lipid levels) was examined in this study by two analytical methods: quantile binning and multivariable regression analysis. Quantile binning was used to convert an individual's PRS to the absolute scale (i.e., plasma lipid value) as previously reported.²⁵ In situations where the correctness of the linearity assumption is undetermined, quantile binning is essential to correct LDL-C changes due to rare functional variants and to combine them with the MRS at the individual level in a representative sample. Multivariable regression analyses, on the other hand, were performed to quantify the predictive utility of predictors (i.e., risk scores) at the group level separately by (sub)group, and the coefficient of determination (denoted R^2) was used to provide a measure of how well the observed outcomes are approximated by the regression predictors in the tested population. The imputed value for lipid-lowering therapy was used in analyses including PRS when analyzing LDL-C.

No formal sample size calculations were performed since both BIO-CVD and NCGM Biobank are

ongoing studies and there is no generally accepted approach to estimating the sample size needed to develop a prediction model like this study.

Significant results are shown as mean \pm SE with P < 0.05 unless otherwise stated.

Results

Imputation of baseline LDL-C level

This study recruited adult patients with high LDL-C and CAD at NCGM; of 315 CAD patients, 157 had a clear history of myocardial infarction, but 158 did not (Table 1). A considerable part of the participants had been prescribed statins, with 19% in the high LDL-C subgroup and 70% in the CAD subgroup (Table 1). For statin, irrespective of its type and dose, the average percent reduction in LDL-C from baseline (or pre-treatment) was approximately 40%. Also, for ezetimibe, the percent reduction in LDL-C was 22% (observation in a single patient) (Fig. S1). Hence, we used these values (40% for statins and 20% for ezetimibe) to impute pre-treatment LDL-C measurements for patients on lipid-lowering therapy.

Rare variants in five FH-related genes

We identified 1,762 variants in five FH-related genes, of which 58 were rare (MAF <0.01) variants with functional significance. The variants (30 in *APOB*, 13 in *LDLR*, 7 in *PCSK9*, 1 in *LDLRAP1*, and 7 in *APOE*) could be classified into three categories—2 disruptive (frameshift and splice-donor each), 13 damaging, and 43 other non-synonymous variants (Table 2 and Table S2)—according to criteria described in the Methods. In a CAD patient, we also identified a gain-of-function type variant for *PCSK9* (indel, TGCCAGCGCCT/-), which appeared to be protective against CAD by exerting LDL-C lowering effects (Table 2). None of the identified rare variants overlapped with variants reported to affect response to statin therapy.²⁶

We evaluated the effect sizes of rare FH-related gene variants compared to a reference group of non-carriers by category to calculate the net increase in LDL-C caused by individual rare variants (see Methods). LDL-C levels increased significantly (P<0.05) in all three categories compared to the reference group: plus 106, 42, and 13 mg/dl for disruptive, damaging, and non-synonymous rare variants, respectively (Fig. 2A). The order of increase was consistent with the predicted pathogenicity

224

225

226

227

228

229

230

231

232

233

234

235

236

237

238

239

240

241

242

243

244

245

246

247

248

249

250

9

of identified rare variants (Fig. 2B) and also with results from another study in Japanese.²² The ratio of carriers for 'disruptive + damaging' variants was significantly ($P < 1 \times 10^{-15}$) higher among CAD and high LDL-C subjects (ratio=0.025 and 0.03, respectively) than in the general population, TMM (ratio=0.002). (Fig. 2C). PRS and composite genetic risk prediction for LDL-C By use of the standardized PRS_{LDL-C} decile classes, we found that PRS_{LDL-C} was shifted towards higher (from 7th to 10th) decile classes among high LDL-C subjects, whereas PRS_{LDL-C} distribution was protruded in the 9th decile class among CAD subjects (Fig. 3C). We examined the correlation between predicted and actual LDL-C levels in newly recruited individuals at NCGM, based on standardized PRS_{LDL-C} decile and estimates of LDL-C increase by rare variant category in Japanese. (Fig. 3D,E). The correlation was stronger for composite genetic risk prediction with both PRS_{LDL-C} and rare variant effects (middle plot; r=0.261, $P=1.7\times10^{-11}$) than conventional genetic risk prediction with PRS_{LDL-C} alone (left plot; r=0.151, $P=1.2\times10^{-4}$). Impacts of PRSs and MRSs on lipid traits Each subgroup (Table 1) had unimodal distributions of HDL-C, triglycerides, and BMI, distinct from LDL-C (Fig. S4). Between high LDL-C and CAD subgroups, there were significant differences in BMI (P=0.004) and HDL-C $(P=9.2\times10^{-18})$ in addition to LDL-C $(P=5.8\times10^{-158})$. We confirmed the consistency (R^2 =0.34—0.86) of two DNA methylation analytical methods (EPIC array and ddPCR; see Fig. S5). Then, we used ddPCR to measure the methylation levels of 13 CpGs (see Table S3) and found that the effect sizes of the CpG-trait association were well correlated with previous multi-ethnic EWAS (Fig. 4A). Furthermore, there were significant differences (P=0.0045 for LDL, $P=3.5\times10^{-7}$ for HDL) in the MRS distribution between the high LDL-C and CAD subgroups (Fig. S6), consistent with phenotypic differences between the subgroups. When the CpGs were analyzed individually, the CpG-trait association was more robust in the CAD subgroup compared to the high LDL-C subgroup for lipid traits (Fig. 4A). This was supported by the results of the MRS-trait association, which involves the cumulative effects of top-hit CpGs previously reported for each lipid trait (Fig. 4B and Table S4). Contrarily, the impact of PRSs on lipid

traits tended to be smaller in the CAD subgroup than in the high LDL-C subgroup. The two risk scores

were also explanatory factors for the variance of lipid traits in the general population (as represented by the KING study cohort). At the same time, there were some differences in their relative influence compared to the high LDL-C and CAD subgroups. Overall, within each subgroup or population, the effects of PRSs and MRSs on lipid traits were additive (Fig. 4B). Although it remains a preliminary finding given the modest sample size in the current non-CAD subgroup, the strength of association between the risk scores and lipid traits appeared to be influenced by CAD status or its related factors (Table S4).

Predictability of lipid traits by risk score models

We compared correlation strengths between predicted and measured lipid trait values using various risk score models to assess individual predictability (Fig.3D-F and Fig. S7). The model incorporating PRS and MRS (plus rare variants for LDL-C) showed a higher correlation than the one using only one risk score, supporting its efficacy in enhancing predictability.

Discussion

This study, focusing on cardiovascular risk, evaluates the relative contribution of genetic predisposition and DNA methylation to plasma lipid levels, by developing a prediction model for dyslipidemia. Our analysis newly demonstrates two key points. First, concerning genetic predisposition, the effect sizes of rare FH-related gene variants are generally more prominent than the integrated effect of common variants (i.e., PRS). Combining the two can increase the accuracy of predicting an individual's genetic predisposition for LDL-C. Second, DNA methylation, which is assumed to reflect an individual's history of environmental exposure, interacts with genetic predisposition to affect an individual's blood lipid levels. Therefore, combining DNA methylation and genetic predisposition can enhance the accuracy of predicting optimal treatment.

As a first step in this study, we have successfully developed an algorithm to predict composite genetic risk for high LDL-C levels. Prioritizing the detection of rare pathogenic variants in population screening, as well as the concurrent use of PRS is a topic of active discussion for genomic conditions that are actionable and adult-onset.²⁷ Thus, a study has shown a risk prediction model that combines rare pathogenic variants, PRS, and individual risk factor variables for breast cancer (i.e., dichotomous

In addition to genetic predisposition, epigenetics, specifically DNA methylation, has attracted attention in mediating gene-environment interactions in cardiometabolic phenotypes. This is because nutritional and lifestyle factors considerably influence epigenetics. Also, EWAS has shown through longitudinal analyses that smoking and alcohol consumption are associated with individual differences in DNA methylation at many CpG sites in the genome, and that such an association between traits and CpG methylation is likely to reflect to a significant degree the reverse causation of cardiometabolic phenotypes, including obesity. Furthermore, it has recently been noted that GWAS and EWAS capture different aspects of the biology of complex traits. Thus, interest has been growing in applying the PRS approaches to DNA methylation data, the so-called MRS. Still, methodological challenges must be resolved in its construction and use as a biomarker for environmental exposures.

Given these circumstances, we have evaluated lipid MRSs containing a list of 13-CpGs in combination with PRS or without PRS through the development of prediction models for individual trait values. We initially selected the 13 CpGs because they showed a strong association with any of

While the clinical benefits of LDL-C lowering are widely acknowledged for the prevention of atherosclerotic cardiovascular diseases, a residual risk beyond LDL-C, including higher plasma levels of triglycerides and triglyceride-related apolipoproteins, has become recognized. In general, management of hypertriglyceridemia starts with lifestyle modification, and the use of drugs may be considered in high-risk individuals with limited benefits from lifestyle modification. This necessitates the encouragement of patient adherence to lifestyle changes or drug regimens.¹

We envision that the combination of PRS (or, more preferably, composite genetic risk prediction) and MRS will contribute to a tailored approach to the management of dyslipidemia and even CAD, as emphasized by the clinical practice guidelines.^{1,4} In view of the considerable individual variability in not only dietary habits but also the LDL-C response to dietary and drug treatment,³⁵ the use of our risk prediction index (exemplified in Fig. S8) in clinical practice may aid patient-doctor communication, facilitating adherence to and optimization of lipid treatment.

There are strengths and limitations in this study. First, we investigated the impact of genetic and DNA methylation variations on dyslipidemia in two risk groups (high LDL-C and CAD subjects), in contrast to the general population and non-CAD subjects. It is a strength that this information can be used to optimize treatment for primary (high LDL-C) and secondary (CAD) prevention of atherosclerotic cardiovascular disease by considering the relative contributions of genetics and

336

337

338

339

340

341

342

343

344

345

346

347

348

349

350

351

352

353

354

355

356

357

358

13

In summary, we conducted an integrative assessment towards precision medicine for dyslipidemia. Our data provided proof-of-concept that an individual's dyslipidemia treatment regimen could be determined more precisely by the relative contribution of genetic predisposition and DNA methylation levels, which reflect past environmental exposures to a significant degree.

Acknowledgments:

We thank the Research Institute, NCGM staff for their technical assistance with DNA preparation and epigenetic analysis.

Sources of funding:

This study was supported by a grant (19A2004) from NCGM and AMED under Grant Number JP22ek0210165 and JSPS KAKENHI Grants (JP20K10514, JP21H03206, JP22H03350).

Disclosures: None

Data availability:

All data produced in the present study are available upon reasonable request to the authors.

368

- 1. Authors/Task Force Members; ESC Committee for Practice Guidelines (CPG); ESC National
- Cardiac Societies. 2019 ESC/EAS guidelines for the management of dyslipidaemias: Lipid
- 371 modification to reduce cardiovascular risk. *Atherosclerosis*. 2019;290:140-205.
- 2. Migliara G, Baccolini V, Rosso A, D'Andrea E, Massimi A, Villari P, De Vito C. Familial
- Hypercholesterolemia: A Systematic Review of Guidelines on Genetic Testing and Patient
- 374 Management. Front Public Health. 2017;5:252
- 375 3. Chiu S, Williams PT, Krauss RM. Effects of a very high saturated fat diet on LDL particles in adults
- with atherogenic dyslipidemia: A randomized controlled trial. *PLoS One*. 2017;12:e0170664.
- 4. Stone NJ, Robinson JG, Lichtenstein AH, Bairey Merz CN, Blum CB, Eckel RH, Goldberg AC, Gordon
- D, Levy D, Lloyd-Jones DM, et al. American College of Cardiology/American Heart Association
- Task Force on Practice Guidelines. 2013 ACC/AHA guideline on the treatment of blood
- 380 cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American
- College of Cardiology/American Heart Association Task Force on Practice Guidelines. *Circulation*.
- 382 **2014**;**129**:**S1**-**45**.
- 5. Dixon DL, Sharma G, Sandesara PB, Yang E, Braun LT, Mensah GA, Sperling LS, Deedwania PC,
- Virani SS. Therapeutic Inertia in Cardiovascular Disease Prevention: Time to Move the Bar. J Am
- 385 *Coll Cardiol*. 2019;74:1728-1731.
- 386 6. Dugué PA, Jung CH, Joo JE, Wang X, Wong EM, Makalic E, Schmidt DF, Baglietto L, Severi G,
- Southey MC, et al. Smoking and blood DNA methylation: an epigenome-wide association study
- and assessment of reversibility. *Epigenetics*. 2020;15:358-368.
- 7. Dugué PA, Wilson R, Lehne B, Jayasekara H, Wang X, Jung CH, Joo JE, Makalic E, Schmidt DF,
- 390 Baglietto L, et al. Alcohol consumption is associated with widespread changes in blood DNA
- methylation: Analysis of cross-sectional and longitudinal data. *Addict Biol.* 2021;26:e12855
- 392 8. Jones AC, Irvin MR, Claas SA, Arnett DK. Lipid Phenotypes and DNA Methylation: a Review of the
- 393 Literature. *Curr Atheroscler Rep.* 2021;23:71.
- 394 9. Santaló J, Berdasco M. Ethical implications of epigenetics in the era of personalized medicine.
- 395 *Clin Epigenetics*. 2022;14:44.
- 10. Jhun MA, Mendelson M, Wilson R, Gondalia R, Joehanes R, Salfati E, Zhao X, Braun KVE, Do AN,
- 397 Hedman ÅK, et al. A multi-ethnic epigenome-wide association study of leukocyte DNA
- methylation and blood lipids. *Nat Commun.* 2021;12:3987.
- 399 11. Ding Y, Hou K, Burch KS, Lapinska S, Privé F, Vilhjálmsson B, Sankararaman S, Pasaniuc B.
- Large uncertainty in individual polygenic risk score estimation impacts PRS-based risk

- 402 12. Evans LM, Romero Villela PN. How rare mutations contribute to complex traits. *Nature*.
- 403 2023;614:418-419.
- 404 13. Torkamani A, Wineinger NE, Topol EJ. The personal and clinical utility of polygenic risk scores. Nat
- 405 Rev Genet. 2018;19:581-590.
- 406 14. Hüls A, Czamara D. Methodological challenges in constructing DNA methylation risk scores.
- 407 *Epigenetics*. 2020;15:1-11.
- 408 15. Nakatochi M, Ichihara S, Yamamoto K, Ohnaka K, Kato Y, Yokota S, Hirashiki A, Naruse K, Asano
- H, Izawa H, et al. Epigenome-wide association study suggests that SNPs in the promoter region
- of RETN influence plasma resistin level via effects on DNA methylation at neighbouring sites.
- 411 *Diabetologia*. 2015;58:2781-2790.
- 412 16. Ruel I, Aljenedil S, Sadri I, de Varennes É, Hegele RA, Couture P, Bergeron J, Wanneh E, Baass A,
- Dufour R, et al. Imputation of Baseline LDL Cholesterol Concentration in Patients with Familial
- Hypercholesterolemia on Statins or Ezetimibe. *Clin Chem.* 2018;64:355-362.
- 415 17. Liu X, Li C, Mou C, Dong Y, Tu Y. dbNSFP v4: a comprehensive database of transcript-specific
- functional predictions and annotations for human nonsynonymous and splice-site SNVs.
- 417 *Genome Med.* 2020;12:103.
- 18. Takeuchi F, Akiyama M, Matoba N, Katsuya T, Nakatochi M, Tabara Y, Narita A, Saw WY, Moon
- S, Spracklen CN, et al. Interethnic analyses of blood pressure loci in populations of East Asian
- and European descent. *Nat Commun.* 2018;9:5052.
- 421 19. Vilhjálmsson BJ, Yang J, Finucane HK, Gusev A, Lindström S, Ripke S, Genovese G, Loh PR, Bhatia
- 422 G, Do R, et al. Modeling Linkage Disequilibrium Increases Accuracy of Polygenic Risk Scores. Am
- 423 *J Hum Genet*. 2015;97:576-592.
- 20. Kanai M, Akiyama M, Takahashi A, Matoba N, Momozawa Y, Ikeda M, Iwata N, Ikegawa S, Hirata
- M, Matsuda K, et al. Genetic analysis of quantitative traits in the Japanese population links cell
- 426 types to complex human diseases. *Nat Genet*. 2018;50:390-400.
- 427 21. Sakaue S, Hirata J, Kanai M, Suzuki K, Akiyama M, Lai Too C, Arayssi T, Hammoudeh M, Al Emadi
- S, Masri BK, et al. Dimensionality reduction reveals fine-scale structure in the Japanese
- population with consequences for polygenic risk prediction. *Nat Commun.* 2020;11:1569.
- 22. Tajima T, Morita H, Ito K, Yamazaki T, Kubo M, Komuro I, Momozawa Y. Blood lipid-related low-
- frequency variants in LDLR and PCSK9 are associated with onset age and risk of myocardial
- infarction in Japanese. *Sci Rep.* 2018;8:8107.
- 23. Takeuchi F, Takano K, Yamamoto M, Isono M, Miyake W, Mori K, Hara H, Hiroi Y, Kato N. Clinical

- Implication of Smoking-Related Aryl-Hydrocarbon Receptor Repressor (AHRR) Hypomethylation
- 435 in Japanese Adults. *Circ J.* 2022;86:986-992.
- 436 24. Shah S, Bonder MJ, Marioni RE, Zhu Z, McRae AF, Zhernakova A, Harris SE, Liewald D, Henders
- 437 AK, Mendelson MM, et al. Improving Phenotypic Prediction by Combining Genetic and
- 438 Epigenetic Associations. *Am J Hum Genet*. 2015;97:75-85.
- 25. Pain O, Gillett AC, Austin JC, Folkersen L, Lewis CM. A tool for translating polygenic scores onto
- the absolute scale using summary statistics. *Eur J Hum Genet*. 2022;30:339-348.
- 26. Yow HY, Hamzah S, Abdul Rahim N, Suppiah V. Pharmacogenomics of response to statin
- treatment and susceptibility to statin-induced adverse drug reactions in Asians: a scoping review.
- 443 *Asian Biomed (Res Rev News).* 2023;17:95-114.
- 444 27. Lacaze P, Manchanda R, Green RC. Prioritizing the detection of rare pathogenic variants in
- population screening. *Nat Rev Genet*. 2023;24:205-206.
- 28. Lee A, Mavaddat N, Wilcox AN, Cunningham AP, Carver T, Hartley S, Babb de Villiers C, Izquierdo
- 447 A, Simard J, Schmidt MK, et al. BOADICEA: a comprehensive breast cancer risk prediction model
- incorporating genetic and nongenetic risk factors. *Genet Med.* 2019;21:1708-1718.
- 29. Khera AV, Won HH, Peloso GM, Lawson KS, Bartz TM, Deng X, van Leeuwen EM, Natarajan P,
- 450 Emdin CA, Bick AG, et al. Diagnostic Yield and Clinical Utility of Sequencing Familial
- Hypercholesterolemia Genes in Patients With Severe Hypercholesterolemia. J Am Coll Cardiol.
- 452 2016;67:2578-2589.
- 30. Natarajan P, Peloso GM, Zekavat SM, Montasser M, Ganna A, Chaffin M, Khera AV, Zhou W,
- Bloom JM, Engreitz JM, et al. Deep-coverage whole genome sequences and blood lipids among
- 455 **16,324** individuals. *Nat Commun*. 2018;9:3391.
- 456 31. Sharifi M, Futema M, Nair D, Humphries SE. Genetic Architecture of Familial
- 457 Hypercholesterolaemia. *Curr Cardiol Rep.* 2017;19:44.
- 458 32. van Dijk SJ, Tellam RL, Morrison JL, Muhlhausler BS, Molloy PL. Recent developments on the role
- of epigenetics in obesity and metabolic disease. Clin Epigenetics. 2015;7:66.
- 33. Wahl S, Drong A, Lehne B, Loh M, Scott WR, Kunze S, Tsai PC, Ried JS, Zhang W, Yang Y, et al.
- Epigenome-wide association study of body mass index, and the adverse outcomes of adiposity.
- 462 *Nature*. 2017;541:81-86.
- 34. Battram T, Gaunt TR, Relton CL, Timpson NJ, Hemani G. A comparison of the genes and genesets
- identified by GWAS and EWAS of fifteen complex traits. *Nat Commun.* 2022;13:7816.
- 35. Boekholdt SM, Hovingh GK, Mora S, Arsenault BJ, Amarenco P, Pedersen TR, LaRosa JC, Waters
- DD, DeMicco DA, Simes RJ, et al. Very low levels of atherogenic lipoproteins and the risk for

467 cardiovascular events: a meta-analysis of statin trials. *J Am Coll Cardiol*. 2014;64:485-494.




Fig. 1. Overview of study design.

The integrative genomic analysis involves GWAS array genotyping, target gene resequencing, and measuring DNA methylation at selected CpG sites. In contrast to two cardiovascular risk groups—high LDL-C and CAD subgroups, individuals in the non-targeted populations (N = 3,801) were used as reference datasets for GWAS array genotyping. The non-CAD subgroup ($N = ^{\sim}164$) was compared to the CAD subgroup by GWAS array genotyping and target gene resequencing. Participants in Tohoku Medical Megabank (TMM) (N = 8.3K) were also used as large *in silico* genetic datasets for the evaluation of rare variant frequencies. Moreover, part (N = 314) of the KING study cohort was used as a reference dataset for DNA methylation analysis.






Fig. 2. Impacts of rare FH-related gene variants on LDL-C level and their prevalence.

An LDL-C increase against the reference group (BIO-CVD subjects without notable rare variants, N = 305) is estimated for three categories, i.e., disruptive, damaging, and non-synonymous (see Methods about the classification), of 5 FH-related gene variants (**A**), based on LDL-C level according to rare variants that were identified by target gene resequencing (**B**). **C**: The percentage of 'disruptive + damaging' variant carriers is shown for populations with different morbidity statuses: high LDL-C (left) and CAD (middle) subgroups and a general population (right; TMM cohort) of Japanese descent.




Fig. 3. Development of a conversion formula from PRS to LDL-C value for PRS-based risk prediction.

First, to define the standardized PRS_{LDL-C} decile classes, data for three population-based cohorts (Kita-Nagoya, Amagasaki, and Ehime) were combined; distribution of PRS_{LDL-C} (**A**) and actual LDL-C for each PRS_{LDL-C} decile class thus standardized (**B**). Then, data for another hospital-based study cohort (NCGM hospital cohort) were used to convert PRS to LDL-C value for the individuals newly recruited at NCGM for rare variant search besides PRS and MRS calculations (see also Fig. S2). **C**: PRS_{LDL-C} distribution is stratified based on standardized PRS_{LDL-C} decile classes for high LDL-C (top) and CAD (bottom) subgroups at NCGM. Correlations are shown between actual LDL-C levels and those predicted by the standardized PRS_{LDL-C} decile class alone (**D**), composite genetic risk (**E**), and composite genetic risk + MRS (**F**) in newly recruited individuals at NCGM (BIO-CVD + NCGM Biobank) with a complete dataset.




Fig. 4. CpG-trait association and prediction of lipid traits by risk scores.

A: Effect sizes for CpG-trait association are shown for triglycerides (left; at 11 CpGs), HDL-C (middle; at 6 CpGs), and LDL-C (right; at 2 CpGs), where comparisons are made between this study and previous multi-ethnic EWAS¹⁰ (top panels), and between high LDL-C and CAD subgroups (bottom panels). **B:** Impacts of two risk scores, PRS and MRS, on lipid traits are estimated by R^2 in high LDL-C (left) and CAD (middle) subgroups and a general population (right; KING study cohort) of Japanese descent separately. *P<0.05, *P<0.001, **P<10-4.

Table 1. Participant characteristics

	High LDL-C (≥160) subjects w/o CAD	CAD subjects	non-CAD subjects		
No. of individuals (F/M)	296 (151/145)	315 (51/264)	164 (54/110)		
Age, yr	64.0 ± 0.7	68.7 ± 0.6	69.7 ± 0.7		
BMI. kg/m ²	23.6 ± 0.2	24.5 ± 0.2	23.6 ± 0.3		
LDL-C, mg/dl	179.4 ± 1.3	98.6 ± 1.7	109.5 ± 2.1		
HDL-C, mg/dl	60.4 ± 1.1	48.7 ± 0.7	56.7 ± 1.1		
Triglycerides, mg/dl	144.3 ± 4.1	143.8 ± 4.4	129.4 ± 5.5		
Smoking habit*					
Never, n (%)	142 (48%)	90 (29%)	61 (37%)		
Former, n (%)	113 (38%)	153 (49%)	76 (46%)		
Current, n (%)	41 (14%)	70 (22%)	27 (16%)		
Complication**					
Hypertension, n (%)	153 (52%)	245 (78%)	114 (70%)		
Diabetes, n (%)	52 (18%)	130 (41%)	46 (28%)		
Hyper-LDL-cholesterolemia, n (%)	296 (100%)	152 (48%)	48 (29%)		
Statin, n (%)	57 (19%)	221 (70%)	47 (29%)		
Ezetimibe, n (%)	13 (4%)	32 (10%)	2 (1%)		
CAD, n (%)***	_	315 (100%)	0 (0%)		

Samples in the table were derived from either the BIO-CVD project or the NCGM Biobank and all but 122 non-CAD individuals were used for resequencing of 5 target genes related to familial hypercholesterolemia (see Methods). CAD, coronary artery disease. LDL-C, low density lipoprotein cholesterol. Of 315 CAD patients, 157 had a clear history of myocardial infarction (MI) but 158 did not: an average number of diseased vessels, 2.0 (0.1) vs 1.8 (0.1); the age of CAD onset, 63.0 yr (1.0) vs 66.9 yr (1.0); left ventricular ejection fraction in echocardiography, 50.7% (1.0) vs 63.9% (0.4) [MI vs non-MI, SE in parentheses].

^{*}The smoking status of 2 individuals in a CAD group is unknown.

^{**} Hypertension and diabetes are defined when individuals are prescribed anti-hypertensive and anti-diabetic drugs, respectively. Hyper-LDL-cholesterolemia is defined when basal LDL-C

≥140 mg/dl (irrespective of treatment with lipid-lowering drugs, statin, and/or ezetimibe) has been indicated by medical records.

***Subjects in a high LDL-C group do not have apparent CAD, although detailed examinations (e.g., coronary angiography) have not been performed in the majority of cases.

Table 2. A list of functional variants identified by target resequencing of FH-related genes

Chr:Pos (GRCh37, hg19)		Ref/Alt allele	Gene Name	Sequence ontology ^a	Clinical Signifi- cance ^b	N of 6, Predicted as Deleterious	FATHM M MKL Coding Pred (C) ^d	LOVD - classifi- cation ^e	Alt allele_freq.					
	SNP								Control (ToMMo; N = 8380)	HL+CAD (N = 610)	χ^2 test, P-value	gnomAD PopMax ^f	LDL-C (mg/dl)	Notes
Disruptive variant	:s													
19:11215971	rs879254510	-/C	LDLR	frameshift	P/LP	_	_	P (ACGS)	N/A	0.0008	2E-04	N/A	290	D131fs
19:11227676	rs778408161	T/C	LDLR	splice_ donor	P/LP	2 of 6	Damaging	LP (ACGS)	6E-05	0.0008	0.015	7E-06	271	Disruptive (FH_Niigata)
Damaging variant	s													
19:11217342	rs875989907	G/A	LDLR	missense	P/LP	6 of 6	Damaging	LP	N/A	0.0008	2E-04	6E-05	233	GnomAD_exome (Asian); 3/49010
19:11221399	rs879254753	T/A	LDLR	missense	P/LP	6 of 6	Damaging	LP	6E-05	0.0008	0.015	N/A	248	Damaging (FH_Wakayama)
19:11224019	N/A	G/A	LDLR	missense	LP	6 of 6	Damaging	LP	6E-05	0.0008	0.015	N/A	225	
19:11226885	rs746959386	C/G	LDLR	missense	P/LP	5 of 6	Damaging	LP	0.0003	0.0016	0.022	1E-04	189 ± 57	
19:11213368	N/A	C/A	LDLR	missense	N/A	6 of 6	Damaging	N/A	N/A	0.0008	2E-04	N/A	210	newly identified
19:11213417	rs749038326	G/A	LDLR	missense	Conflict- ing (LP/VUS /LB*)	6 of 6	Damaging	P, LP	N/A	0.0008	2E-04	3E-04	196	GnomAD_exome (Asian); 14/49010
19:11216066	N/A	C/T	LDLR	missense	N/A	6 of 6	Damaging	P (ACGS)	N/A	0.0008	2E-04	N/A	212	c.466_484dup
19:11227613	rs201102492	G/A	LDLR	missense	Conflict- ing (P/LP/V US)	6 of 6	Damaging	LP (ACGS)	6E-05	0.0008	0.015	2E-04	165	
2:21228367	N/A	G/T	APOB	missense	N/A	4 of 6	Damaging	N/A	N/A	0.0008	2E-04	N/A	202	newly identified

2:21233912	rs759277505	G/A	АРОВ	missense	N/A	5 of 6	Damaging	N/A	0.00018	0.0016	0.0004	1E-05	187 ± 17	A subject possessing rs752849346 (LDLRAP1) and rs564427867 (PCSK9) concomitantly.
2:21236137	rs780170292	C/T	APOB	missense	VUS	5 of 6	Damaging	N/A	6E-05	0.0008	0.015	3E-04	170	
2:21225680	rs375471570	G/A	APOB	missense	VUS	4 of 6	Damaging	N/A	6E-05	0.0008	0.015	1E-04	210	
2:21229473	rs199689957	С/Т	АРОВ	missense	VUS	2 of 6	Damaging	N/A	N/A	0.0008	2E-04	2E-04	293	GnomAD_exome (Asian); 0/49006. A subject possessing rs564427867 (PCSK9) concomitantly.
Gain-of-Function variants														
1:55521767	N/A	TGCCAGCGCCT/-	PCSK9	frameshift		_	_	_	N/A	0.0008	2E-04	N/A	46	NP_777596.2:p.Cys301Glyfs Ter? newly identified

^aThe highest priority ontology found among the variant–transcript interactions. The terms used are the standard feature descriptions given by the Sequence Ontology Project.

^b Clinical significance is the consensus interpretation of the submissions for all conditions for this variant. Primarily based on ACMG Classifications: P, pathogenic; LP, likely pathogenic; VUS, variant of uncertain significance; LB, likely benign; B, benign.

^cVariant effect predictor tools tested are: SIFT, PolyPhen2, Mutation Taster, Mutation Assessor, FATHMM, and FATHMM-MKL.

d If a FATHMM-MKL coding score (PMID: 25583119) is >0.5 (or rank score >0.28317), the corresponding nsSNV is predicted as "DAMAGING"; otherwise it is predicted as "TOLERATED".

e Variant classification and interpretation by the Association for Clinical Genomic Science (ACGS) is shown when applicable. For abbreviations, refer to the ACMG Classifications above.

^fPopMax refers to the gnomAD subpopulation with the highest allele frequency

^{*}Despite one submission (SCV000503122.1) indicating LB, the others claim either P (6 submissions) or LP (3 submissions) for the pathogenicity of this variant.